Figg WD - Search Results

1

Urinary aHGF, IGFBP3 and OPN as diagnostic and prognostic biomarkers for prostate cancer.

Prager AJ, Peng CR, Lita E, McNally D, Kaushal A, Sproull M, Compton K, Dahut WL, Figg WD, Citrin D, Camphausen KA. Prager AJ, et al. Among authors: figg wd. Biomark Med. 2013 Dec;7(6):831-41. doi: 10.2217/bmm.13.112. Biomark Med. 2013. PMID: 24266816 Free PMC article.

2

Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer.

Figg WD, Sartor O, Cooper MR, Thibault A, Bergan RC, Dawson N, Reed E, Myers CE. Figg WD, et al. Am J Med. 1995 Apr;98(4):412-4. doi: 10.1016/S0002-9343(99)80323-4. Am J Med. 1995. PMID: 7535978 Clinical Trial. No abstract available.

3

Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer.

Figg WD, Ammerman K, Patronas N, Steinberg SM, Walls RG, Dawson N, Reed E, Sartor O. Figg WD, et al. Cancer Invest. 1996;14(6):513-7. doi: 10.3109/07357909609076896. Cancer Invest. 1996. PMID: 8951355

4

Elevated carcinoembryonic antigen in patients with androgen-independent prostate cancer.

Feuer JA, Lush RM, Venzon D, Duray P, Tompkins A, Sartor O, Figg WD. Feuer JA, et al. Among authors: figg wd. J Investig Med. 1998 Feb;46(2):66-72. J Investig Med. 1998. PMID: 9549229

5

Taxanes in hormone-refractory prostate cancer.

Kang MH, Figg WD, Dahut W. Kang MH, et al. Among authors: figg wd. Cancer Pract. 1999 Sep-Oct;7(5):270-2. doi: 10.1046/j.1523-5394.1999.75005.x. Cancer Pract. 1999. PMID: 10687598 Review. No abstract available.

6

8:45-9:00. Using PET 18F-FDG, 11CO, and 15O-water for Monitoring Prostate Cancer During a Phase II Anti-angiogenic Drug Trial with Thalidomide.

Kurdziel K, Bacharach S, Carrasquillo J, Huebsch S, Whatley M, Sellers D, Steinberg S, Libutti S, Pluda J, Reed E, Dahut W, Figg W. Kurdziel K, et al. Clin Positron Imaging. 2000 Jul;3(4):144. doi: 10.1016/s1095-0397(00)00056-x. Clin Positron Imaging. 2000. PMID: 11150747

7

Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer.

Rudek MA, Figg WD, Dyer V, Dahut W, Turner ML, Steinberg SM, Liewehr DJ, Kohler DR, Pluda JM, Reed E. Rudek MA, et al. Among authors: figg wd. J Clin Oncol. 2001 Jan 15;19(2):584-92. doi: 10.1200/JCO.2001.19.2.584. J Clin Oncol. 2001. PMID: 11208854 Clinical Trial.

8

Reversible sideroblastic anemia associated with the tetracycline analogue COL-3.

Rudek MA, Horne M, Figg WD, Dahut W, Dyer V, Pluda JM, Reed E. Rudek MA, et al. Among authors: figg wd. Am J Hematol. 2001 May;67(1):51-3. doi: 10.1002/ajh.1076. Am J Hematol. 2001. PMID: 11279658 Free article.

9

Drug-induced lupus associated with COL-3: report of 3 cases.

Ghate JV, Turner ML, Rudek MA, Figg WD, Dahut W, Dyer V, Pluda JM, Reed E. Ghate JV, et al. Among authors: figg wd. Arch Dermatol. 2001 Apr;137(4):471-4. Arch Dermatol. 2001. PMID: 11295928 Clinical Trial.

10

Thalidomide neuropathy in patients treated for metastatic prostate cancer.

Molloy FM, Floeter MK, Syed NA, Sandbrink F, Culcea E, Steinberg SM, Dahut W, Pluda J, Kruger EA, Reed E, Figg WD. Molloy FM, et al. Among authors: figg wd. Muscle Nerve. 2001 Aug;24(8):1050-7. doi: 10.1002/mus.1109. Muscle Nerve. 2001. PMID: 11439380 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

793 results

Search Page

Filters